The Vetr crowd upgraded its rating for Juno Therapeutics Inc (NASDAQ:JUNO) on Monday from 4 stars (Buy), issued five days ago, to 5 stars (Strong Buy). Crowd sentiment at the time of the upgrade was mostly positive, with 87 percent of Vetr user rating bullish.
Share price in the biotech company experienced a fairly substantial correction following Friday's earnings report that saw revenue exceed expectations to the tune of nearly $6 million, while EPS remained in the red, meeting estimates of $(0.71).
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The underwhelming report resulted in a more than 8.5 percent drop for the stock on Friday. That continued into the next week and Juno finished today's trading day at $22.16, about $3.50 below its pre-earnings close.
Learn how crowdsourced ratings could help you time the market.
Currently, the Vetr crowd's average target price is up at $27.94, which is still well below the average analyst target price of $34.50. Less than 2 percent of Vetr users are holding JUNO in their watch lists.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.